'Tdf ftc' diaporamas de présentation

This program is supported by an educational grant from

872 views • 72 slides

Evoluzione delle strategie terapeutiche in HIV

809 views • 64 slides

Manuel Battegay Div. Infectious Diseases & Hospital Epidemiology

Manuel Battegay Div. Infectious Diseases & Hospital Epidemiology. HIV complications and morbidity. Content. Introduction Selected specific adverse events ART and body shape changes ART, HIV and metabolism Cardiovascular risk general remarks ART and Lipids

751 views • 62 slides

749 views • 60 slides

HIV Update Ardis Moe, M.D. amoe@mednet.ucla UCLA CARE clinic/NEVHC Van Nuys 21 June 2014

HIV Update Ardis Moe, M.D. amoe@mednet.ucla.edu UCLA CARE clinic/NEVHC Van Nuys 21 June 2014. I do not have any financial arrangements or affiliations with commercial sponsors which have direct interest in the subject matter. Goals:. Discuss PREP and PEP options DHHS treatment options

644 views • 48 slides

HIV Preexposure Prophylaxis ( PrEP ) 2019

HIV Preexposure Prophylaxis ( PrEP ) 2019. Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York City, New York. Financial Relationships With Commercial Entities.

753 views • 42 slides

CROI 2010

538 views • 39 slides

Feedback from 15th IAS Conference 13-18 August 2006 Simon Collins HIV i-Base

Feedback from 15th IAS Conference 13-18 August 2006 Simon Collins HIV i-Base. Feedback from 15th IAS Conference. Treatment access New drugs New strategies: boosted-PI monotherapy Other issues. Feedback from 15th IAS Conference. Treatment access

467 views • 37 slides

Kimberly Smith, Winkler Weinberg, Edwin DeJesus, Margaret Fischl, Qiming Liao, Lisa Ross and

The ALERT Study: A Planned Week 24 Interim Analysis of Once Daily Boosted Fosamprenavir or Atazanavir with Tenofovir/Emtricitabine. Kimberly Smith, Winkler Weinberg, Edwin DeJesus, Margaret Fischl, Qiming Liao, Lisa Ross and Tracey Lancaster. Background.

507 views • 36 slides

BORDERNETwork Training on

319 views • 26 slides

Comparison of NNRTI vs NNRTI

903 views • 23 slides

M Harris, S Guillemi , K Chan, B Yip , M Hull, V Dias Lima, R Hogg, J Montaner

EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF) TO ABACAVIR (ABC)-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), WITH OR WITHOUT ATAZANAVIR. M Harris, S Guillemi , K Chan, B Yip , M Hull, V Dias Lima, R Hogg, J Montaner. Abstract #: WEAB0202

289 views • 16 slides

Andrew Hill, Pharmacology and Therapeutics, Liverpool University, UK

Is the pricing of antiretrovirals equitable? Analysis of antiretroviral drug prices in 20 low and middle income countries. Andrew Hill, Pharmacology and Therapeutics, Liverpool University, UK Jintanat Ananworanich, HIVNAT, Thai Red Cross AIDS Research Center , Bangkok, Thailand

443 views • 15 slides

Public Engagement with HIV Science Melbourne, 22 of July, 2014

302 views • 15 slides

The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit

234 views • 12 slides

Drug Exposure and Correlates of Oral and Topical ARV Protection

201 views • 11 slides

Comparison of PI vs PI

Comparison of PI vs PI. ATV vs ATV/r BMS 089 LPV/r mono vs LPV/r + ZDV/3TC MONARK LPV/r QD vs BID M02-418 M05-730 A5073 ATV/r vs FPV/r ALERT FPV/r vs LPV/r KLEAN SQV/r vs LPV/r GEMINI ATV/r vs LPV/r CASTLE DRV/r vs LPV/r ARTEMIS.

151 views • 6 slides

Comparison of PI vs PI

ATV vs ATV/r BMS 089 LPV/r mono vs LPV/r + ZDV/3TC MONARK LPV/r QD vs BID M02-418 M05-730 A5073 ATV/r vs FPV/r ALERT FPV/r vs LPV/r KLEAN SQV/r vs LPV/r GEMINI ATV/r vs LPV/r CASTLE DRV/r vs LPV/r ARTEMIS. Comparison of PI vs PI.

137 views • 6 slides

Comparison of NRTI combinations

260 views • 5 slides

Comparison of PI vs PI

Comparison of PI vs PI. ATV vs ATV/r BMS 089 LPV/r mono vs LPV/r + ZDV/3TC MONARK LPV/r QD vs BID M02-418 M05-730 A5073 ATV/r vs FPV/r ALERT FPV/r vs LPV/r KLEAN SQV/r vs LPV/r GEMINI ATV/r vs LPV/r CASTLE DRV/r vs LPV/r ARTEMIS. ALERT.

164 views • 5 slides